Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC
To evaluate the efficacy and safety of trifluridine/tipiracil combined with fufuquitinib versus trifluridine/tipiracil and fufuquitinib in patients with unresectable metastatic colorectal cancer.
Metastatic Colorectal Cancer|Drug Therapy
DRUG: trifluridine/tipiracil combined with fufuquitinib|DRUG: fufuquitinib|DRUG: Trifluridine/tipiracil
Progression-free survival, up to 24 weeks
Total survival time, up to 2 years
To evaluate the efficacy and safety of trifluridine/tipiracil combined with fufuquitinib versus trifluridine/tipiracil and fufuquitinib in patients with unresectable metastatic colorectal cancer.